Evaluation of cancer testis antigen (CT10, PRAME) and MHC I expression in high-grade urothelial carcinoma of the bladder
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Evaluation of cancer testis antigen (CT10, PRAME) and MHC I expression in high-grade urothelial carcinoma of the bladder
Authors
Keywords
Bladder cancer, Urothelial carcinoma, Inflammation, Cancer testis antigens, Major histocompatibility complex I, Prognosis
Journal
VIRCHOWS ARCHIV
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-09-04
DOI
10.1007/s00428-019-02661-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Expression of cancer–testis antigens in esophageal cancer and their progress in immunotherapy
- (2019) Yujie Zhang et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Immunotherapy in nonmuscle invasive bladder cancer
- (2019) Mohit Gupta et al. CURRENT OPINION IN ONCOLOGY
- Basal subtype bladder tumours demonstrate a “hot” immunophenotype
- (2018) Anjelica Hodgson et al. HISTOPATHOLOGY
- Clinical Significance of Immunohistochemical Expression of Cancer/Testis Tumor-associated Antigens (MAGE-A1, MAGE-A3/4, NY-ESO-1) in Patients with Non-small Cell Lung Cancer
- (2018) Josip Joachim Grah et al. TUMORI
- Cancer/testis antigens (CTAs) expression in resected lung cancer
- (2018) Shi Jin et al. OncoTargets and Therapy
- Strong Expression of Cancertestis Antigens CTAG1B and MAGEA3 Is Correlated with Unfavourable Histopathological Features and MAGEA3 Is Associated with Worse Progression-Free Survival in Urothelial Bladder Cancer
- (2018) Eva Maria Lausenmeyer et al. UROLOGIA INTERNATIONALIS
- p53 immunohistochemistry in high-grade urothelial carcinoma of the bladder is prognostically significant
- (2017) Anjelica Hodgson et al. HISTOPATHOLOGY
- Tumour front inflammation and necrosis are independent prognostic predictors in high-grade urothelial carcinoma of the bladder
- (2017) Anjelica Hodgson et al. JOURNAL OF CLINICAL PATHOLOGY
- Immunotherapy for the Treatment of Urothelial Carcinoma
- (2017) Nicholas M. Donin et al. JOURNAL OF UROLOGY
- Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
- (2017) Padmanee Sharma et al. LANCET ONCOLOGY
- Early gastric cancer frequently has high expression of KK-LC-1, a cancer-testis antigen
- (2017) Nobue Futawatari et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
- (2017) Thomas Powles et al. JAMA Oncology
- Rejection versus escape: the tumor MHC dilemma
- (2016) Federico Garrido et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The urgent need to recover MHC class I in cancers for effective immunotherapy
- (2016) Federico Garrido et al. CURRENT OPINION IN IMMUNOLOGY
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- The prognostic effect of tumour-infiltrating lymphocytic subpopulations in bladder cancer
- (2015) T. Horn et al. WORLD JOURNAL OF UROLOGY
- Oncogenic cancer/testis antigens: prime candidates for immunotherapy
- (2015) Morten F. Gjerstorff et al. Oncotarget
- The PTEN pathway in Tregs functions as a critical driver of the immunosuppressive tumor microenvironment and tolerance to apoptotic cells
- (2015) Madhav Sharma et al. Journal for ImmunoTherapy of Cancer
- Cytokines as effectors and predictors of responses in the treatment of bladder cancer by bacillus Calmette–Guérin
- (2014) Xiaoxuan Liu et al. Future Oncology
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- Therapeutic vaccines for cancer: an overview of clinical trials
- (2014) Ignacio Melero et al. Nature Reviews Clinical Oncology
- Antigen-specific vaccines for cancer treatment
- (2014) Maria Tagliamonte et al. Human Vaccines & Immunotherapeutics
- Immunotherapeutic strategies for bladder cancer
- (2014) Mathieu F Chevalier et al. Human Vaccines & Immunotherapeutics
- Cause and Consequence of Cancer/Testis Antigen Activation in Cancer
- (2013) Angelique W. Whitehurst Annual Review of Pharmacology and Toxicology
- Perioperative Chemotherapy in Muscle-invasive Bladder Cancer: Overview and the Unmet Clinical Need for Alternative Adjuvant Therapy as Studied in the MAGNOLIA Trial
- (2013) Marc Colombel et al. EUROPEAN UROLOGY
- Cancer Peptide Vaccine Therapy Developed from Oncoantigens Identified through Genome-wide Expression Profile Analysis for Bladder Cancer
- (2012) W. Obara et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- FOXP3 and survival in urinary bladder cancer
- (2011) Malin E. Winerdal et al. BJU INTERNATIONAL
- Expression of MAGE-A and NY-ESO-1 cancer/testis antigens in medullary breast cancer: a retrospective immunohistochemical study
- (2011) Božica Matković et al. CROATIAN MEDICAL JOURNAL
- Markers Predicting Response to Bacillus Calmette-Guérin Immunotherapy in High-Risk Bladder Cancer Patients: A Systematic Review
- (2011) Tahlita C.M. Zuiverloon et al. EUROPEAN UROLOGY
- Expression profile of cancer-testis genes in transitional cell carcinoma of the bladder
- (2011) Bo Yin et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now